New imaging agent for diagnosing certain tumors
a Novel Dual-Targeting Molecular Probe TATE-RGD for the Diagnostic Integration of SSTR2 and αvβ3 Positive Tumors
This study is testing a new imaging agent to see if it can better detect certain tumors compared to standard imaging methods.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT06632860 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates a novel dual-targeting imaging agent, 68Ga-TATE-RGD, designed to enhance the diagnosis of tumors that express somatostatin receptors and integrin αvβ3. The study aims to compare the effectiveness of this new tracer against traditional imaging methods in detecting neuroendocrine tumors and other cancers. Participants will undergo PET/CT scans using both 68Ga-TATE-RGD and 18F-FDG to assess the diagnostic capabilities of the new agent. The research builds on previous findings that suggest dual-targeting may improve tumor detection rates.
Who should consider this trial
Good fit: Ideal candidates include patients with histologically confirmed cancers that express SSTR2 and αvβ3.
Not a fit: Patients with known allergies to TATE-RGD or those with medical conditions that may interfere with compliance may not benefit from this study.
Why it matters
Potential benefit: If successful, this imaging agent could lead to more accurate diagnoses and better-targeted treatments for patients with specific types of tumors.
How similar studies have performed: Previous studies have shown promising results with similar dual-targeting approaches, indicating potential for success in this novel application.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * histologically confirmed various cancer patients; * 68Ga-TATE-RGD and 18F-FDG PET/CT within a week; * signed written consent. Exclusion Criteria: * known allergy against TATE-RGD; * any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
Where this trial is running
Beijing, Beijing Municipality
- Peking Union Medical College Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Zhaohui Zhu
- Email: 13611093752@163.com
- Phone: 86-13611093752
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.